SCHEMBL13719293

SCHEMBL13719293

Cn1c(=O)n(N2CCN(C(=O)OC(C)(C)C)CC2)c2cccnc21

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.50
DTYMK P23919 1/20 0.46
GPR119 Q8TDV5 5/20 0.44
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
CCNK O75909 1/20 0.40
CDK12 Q9NYV4 1/20 0.40
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
ACHE P22303 1/20 0.39
GRM5 P41594 1/20 0.39
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
PBRM1 Q86U86 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3764320 0.81 PIK3CA (0.51) POLBDTYMKGPR119DDB1CRBN
SCHEMBL27713892 0.74 FEN1 (0.40)
SCHEMBL26671857 0.73 GPR119 (0.49) POLBDTYMKGPR119DDB1CRBN
SCHEMBL23293467 0.72 POLB (0.49) POLBDTYMKGPR119CHRM2CHRM4
SCHEMBL2715768 0.70 POLB (0.57) POLBDTYMKGPR119CKS1BSKP1
SCHEMBL31046329 0.70 POLB (0.57) POLBDTYMKGPR119CKS1BSKP1
SCHEMBL30339737 0.70 DDB1 (0.55) POLBDTYMKGPR119CHRM2CHRM4
SCHEMBL24101859 0.70 DDB1 (0.55) POLBDTYMKGPR119CHRM2CHRM4
SCHEMBL30292496 0.69 POLB (0.56) POLBDTYMKGPR119CKS1BSKP1
SCHEMBL10317314 0.69 POLB (0.58) POLBDTYMKGPR119CKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2524917-B1 FUSED PYRIDINE DERIVATIVES SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD (CN) 2018-06-27 EP disclosed
US-8680089-B2 Fused pyridine derivatives Xuanzhu Pharma Co., Ltd. (CN) 2014-03-25 US disclosed
EP-2524917-A1 FUSED PYRIDINE DERIVATIVES Xuanzhu Pharmaco., Ltd. (CN) 2012-11-21 EP disclosed
US-20120289497-A1 FUSED PYRIDINE DERIVATIVES Xuanzhu Pharma Co., Ltd. (CN) 2012-11-15 US disclosed
CN-102127072-A Pyridine cyclo-derivative SHANDONG XUANZHU PHARMACEUTICAL CO LTD 2011-07-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289497-A1 FUSED PYRIDINE DERIVATIVES GPR119, INSR, IAPP POLB 3339/4885DTYMK 3156/4885GPR119 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.